Non-interventional, open-label, single group, multicentric post-marketing surveillance to monitor the safety and effectiveness of AVAMYS nasal spray administered in Korean patients according to the prescribing information.

An Open Label, Multi-centre, Non-interventional Post-marketing Surveillance (PMS) to Monitor the Safety and Effectiveness of Avamys® Administered in Korean Patients According to the Prescribing Information

Korean patients administered fluticasone furoate according to the Prescription information

Drug: fluticasone furoate group

patients who are administered fluticasone furoate at least once

Other Name: according to label and physician's decision

Eligibility

Ages Eligible for Study:

2 Years and older

Genders Eligible for Study:

Both

Accepts Healthy Volunteers:

No

Sampling Method:

Probability Sample

Study Population

Patients administrated AVAMYS nasal spray at the site

Criteria

All subjects must satisfy the following criteria.

Subject who is treated with AVAMYS nasal spray for the first time.

Subject who is treated due to symptoms of seasonal and perennial allergic rhinitis in adults and children ≥2 years.

Subject who is considered to follow the PMS protocol by an investigator.

Subject who is contactable via telephone.

Subject who is treated with AVAMYS nasal spray according to its prescribing information.

As considering the characteristic of the observational post marketing surveillance, the exclusion criteria is not strict. All investigators should prescribe AVAMYS nasal spray according to prescribing information which approved in Korea.

All subjects must not satisfy the following criteria.

Subject who has hypersensitivity to its ingredients.

As corticosteroids can slow the healing of wounds, if a subject who has surgery on his/her nose recently, or has a sore in his/her nose, or if his/her nose has been injured, the subject does not use AVAMYS nasal spray until his/her nose has healed.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01001130